Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00162799|
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : June 23, 2006
|Condition or disease||Intervention/treatment||Phase|
|Insulin Resistance||Drug: Triflusal (DCI)||Phase 2|
Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled.
Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days
Washout period: 30 days
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity|
|Study Start Date :||July 2002|
|Estimated Study Completion Date :||December 2004|
- Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).
- Reduction antropometric measures associated with insulin resistance and arterial hypertension.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00162799
|Unitat de Diabetologia, Endocrinologia y Nutrición Hosp Josep Trueta|
|Girona, Spain, 17007|
|Principal Investigator:||Jose Manuel Fernández del Real, Dr||Unidad Diabetología. Serv Endocrino Hosp Josep Trueta|